 EMERYVILLE, Calif., Aug. 03, 2020 GLOBE NEWSWIRE -- Gritstone Oncology Nasdaq: GRTS, a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today announced presentations at two upcoming investor conferences in August. Karin Jooss, Ph.D., executive vice president of research and chief scientific officer, will present at the William Blair Biotech Focus Conference 2020 on Wednesday, August 5, 2020 at 2:25 p.m. ET. Andrew Allen, M.D., Ph.D., co-founder, president and chief executive officer, will present at the BTIG Biotechnology Conference 2020 on Tuesday, August 11, 2020 at 2:00 p.m. ET.A live webcast will be available within the Investors Media section of the Gritstone Oncology website at An archived replay will be accessible for 30 days following the event.About Gritstone Oncology Gritstone Oncology Nasdaq: GRTS, a clinical-stage biotechnology company, is developing the next generation of cancer immunotherapies to fight multiple cancer types. Gritstone develops its products by leveraging two key pillarssecond, a proprietary machine learning-based platform, Gritstone EDGETM, which is designed to predict, from a routine tumor biopsy, the tumor-specific neoantigens TSNA that are presented on a patients tumor cells; and second, the ability to develop and manufacture potent immunotherapies utilizing patients TSNA to potentially drive the patients immune system to specifically attack and destroy tumors. The companys individualized neoantigen-based immunotherapy, GRANITE, and its off the shelf shared neoantigen-based immunotherapy, SLATE, are being evaluated in clinical studies. Novel tumor-specific antigens can also provide targets for bispecific antibody BiSAb therapeutics for solid tumors, and Gritstones BiSAb program is currently in lead optimization. For more information, please visit gritstoneoncology.com.Contacts Media: Dan Budwick 1AB 973 271-6085 Alexandra Santos Wheelhouse Life Science Advisors 510 871-6161 